vs
Prestige Consumer Healthcare Inc.（PBH）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是ROGERS CORP的1.4倍（$283.4M vs $200.5M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 2.2%，领先14.2%），ROGERS CORP同比增速更快（5.2% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $1.1M），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -3.3%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
PBH vs ROG — 直观对比
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $200.5M |
| 净利润 | $46.7M | $4.5M |
| 毛利率 | 55.5% | 32.2% |
| 营业利润率 | 29.1% | — |
| 净利率 | 16.5% | 2.2% |
| 营收同比 | -2.4% | 5.2% |
| 净利润同比 | -23.5% | 421.4% |
| 每股收益（稀释后） | $0.97 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $200.5M | ||
| Q4 25 | $283.4M | $201.5M | ||
| Q3 25 | $274.1M | $216.0M | ||
| Q2 25 | $249.5M | $202.8M | ||
| Q1 25 | $296.5M | $190.5M | ||
| Q4 24 | $290.3M | $192.2M | ||
| Q3 24 | $283.8M | $210.3M | ||
| Q2 24 | $267.1M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $46.7M | $4.6M | ||
| Q3 25 | $42.2M | $8.6M | ||
| Q2 25 | $47.5M | $-73.6M | ||
| Q1 25 | $50.1M | $-1.4M | ||
| Q4 24 | $61.0M | $-500.0K | ||
| Q3 24 | $54.4M | $10.7M | ||
| Q2 24 | $49.1M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 55.5% | 31.5% | ||
| Q3 25 | 55.3% | 33.5% | ||
| Q2 25 | 56.2% | 31.6% | ||
| Q1 25 | 57.3% | 29.9% | ||
| Q4 24 | 55.5% | 32.1% | ||
| Q3 24 | 55.5% | 35.2% | ||
| Q2 24 | 54.7% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 29.1% | 3.5% | ||
| Q3 25 | 29.1% | 7.3% | ||
| Q2 25 | 28.8% | -33.3% | ||
| Q1 25 | 29.8% | -0.2% | ||
| Q4 24 | 31.7% | -6.6% | ||
| Q3 24 | 29.7% | 6.9% | ||
| Q2 24 | 27.0% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 16.5% | 2.3% | ||
| Q3 25 | 15.4% | 4.0% | ||
| Q2 25 | 19.0% | -36.3% | ||
| Q1 25 | 16.9% | -0.7% | ||
| Q4 24 | 21.0% | -0.3% | ||
| Q3 24 | 19.2% | 5.1% | ||
| Q2 24 | 18.4% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.97 | $0.20 | ||
| Q3 25 | $0.86 | $0.48 | ||
| Q2 25 | $0.95 | $-4.00 | ||
| Q1 25 | $1.00 | $-0.08 | ||
| Q4 24 | $1.22 | $-0.04 | ||
| Q3 24 | $1.09 | $0.58 | ||
| Q2 24 | $0.98 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $195.8M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $1.2B |
| 总资产 | $3.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $195.8M | ||
| Q4 25 | $62.4M | $197.0M | ||
| Q3 25 | $119.1M | $167.8M | ||
| Q2 25 | $139.5M | $157.2M | ||
| Q1 25 | $97.9M | $175.6M | ||
| Q4 24 | $50.9M | $159.8M | ||
| Q3 24 | $51.5M | $146.4M | ||
| Q2 24 | $34.3M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.8B | $1.2B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.7B | $1.3B | ||
| Q2 24 | $1.7B | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $3.5B | $1.4B | ||
| Q3 25 | $3.4B | $1.4B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.5B | ||
| Q4 24 | $3.3B | $1.5B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.3B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $1.1M |
| 自由现金流率自由现金流/营收 | 26.6% | 0.5% |
| 资本支出强度资本支出/营收 | 1.1% | 2.3% |
| 现金转化率经营现金流/净利润 | 1.68× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $267.2M | $70.1M |
8季度趋势，按日历期对齐
| Q1 26 | — | $5.8M | ||
| Q4 25 | $78.3M | $46.9M | ||
| Q3 25 | $57.5M | $28.9M | ||
| Q2 25 | $79.0M | $13.7M | ||
| Q1 25 | $61.8M | $11.7M | ||
| Q4 24 | $65.1M | $33.7M | ||
| Q3 24 | $69.8M | $42.4M | ||
| Q2 24 | $54.8M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $75.3M | $42.2M | ||
| Q3 25 | $55.4M | $21.2M | ||
| Q2 25 | $78.2M | $5.6M | ||
| Q1 25 | $58.4M | $2.1M | ||
| Q4 24 | $63.5M | $18.3M | ||
| Q3 24 | $67.8M | $25.2M | ||
| Q2 24 | $53.6M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 26.6% | 20.9% | ||
| Q3 25 | 20.2% | 9.8% | ||
| Q2 25 | 31.3% | 2.8% | ||
| Q1 25 | 19.7% | 1.1% | ||
| Q4 24 | 21.9% | 9.5% | ||
| Q3 24 | 23.9% | 12.0% | ||
| Q2 24 | 20.1% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.1% | 2.3% | ||
| Q3 25 | 0.8% | 3.6% | ||
| Q2 25 | 0.3% | 4.0% | ||
| Q1 25 | 1.2% | 5.0% | ||
| Q4 24 | 0.5% | 8.0% | ||
| Q3 24 | 0.7% | 8.2% | ||
| Q2 24 | 0.4% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.68× | 10.20× | ||
| Q3 25 | 1.36× | 3.36× | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | 3.96× | ||
| Q2 24 | 1.12× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
ROG
暂无分部数据
